Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2013 · 10-Q
Revenue$8.12M$8.12M−33.3% vs Q3 2012 Net Income-$2.30M-$2.30MN/M vs Q3 2012 EPS Diluted-$0.05-$0.05N/M vs Q3 2012 Gross Profit$2,237,265−31.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$640,024−40.5% Free Cash Flowderived$598,970−43.6% Margins · derivedGross margin27.6%+0.9 pt vs Q3 2012
Operating margin-33.1%−46.4 pt vs Q3 2012
Net margin-28.4%−39.0 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 14, 2013 · 45 d after period end